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Abstract
Background: Treatment standard for patients with rectal cancer depends on the initial staging and includes
surgical resection, radiotherapy as well as chemotherapy. For stage II and III tumors, radiochemotherapy should be
performed in addition to surgery, preferentially as preoperative radiochemotherapy or as short-course
hypofractionated radiation. Advances in surgical approaches, especially the establishment of the total mesorectal
excision (TME) in combination with sophisticated radiation and chemotherapy have reduced local recurrence rates
to only few percent. However, due to the high incidence of rectal cancer, still a high absolute number of patients
present with recurrent rectal carcinomas, and effective treatment is therefore needed.
Carbon ions offer physical and biological advantages. Due to their inverted dose profile and the high local dose
deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in
comparison to photons, carbon ions offer an increase relative biological effectiveness (RBE), which can be
calculated between 2 and 5 depending on the cell line as well as the endpoint analyzed.
Japanese data on the treatment of patients with recurrent rectal cancer previously not treated with radiation
therapy have shown local control rates of carbon ion treatment superior to those of surgery. Therefore, this
treatment concept should also be evaluated for recurrences after radiotherapy, when dose application using
conventional photons is limited. Moreover, these patients are likely to benefit from the enhanced biological
efficacy of carbon ions.
Methods and design: In the current Phase I/II-PANDORA-01-Study the recommended dose of carbon ion
radiotherapy for recurrent rectal cancer will be determined in the Phase I part, and feasibilty and progression-free
survival will be assessed in the Phase II part of the study.
Within the Phase I part, increasing doses from 12 × 3 Gy E to 18 × 3 Gy E will be applied.
The primary endpoint in the Phase I part is toxicity, the primary endpoint in the Phase II part is progression-free
survival.
Discussion: With conventional photon irradiation treatment of recurrent rectal cancer is limited, and the clinical
effect is only moderate. With carbon ions, an improved outcome can be expected due to the physical and
biological characteristics of the carbon ion beam. However, the optimal dose applicable in this clincial situation as
re-irradiation still has to be determined. This, as well as efficacy, is to be evaluated in the present Phase I/II trial.
Trial registration: NCT01528683
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Treatment of rectal cancer after primary diagnosis
depends on initial staging and includes surgical resec-
tion, radiation therapy as well as chemotherapy. For T1-
2 tumors without positive lymph nodes, surgical resec-
t i o na l o n ef o l l o w e db yc l o s eoncological follow-up is
recommended. For node-negative T3 tumors, surgery
should be followed by radiochemotherapy followed by
adjuvant chemotherapy. In patients with node positive
T1-3 tumors, surgical resection should also be followed
by radiochemotherapy and adjuvant chemotherapy [1].
There is substantial evidence that radiation therapy
prior to surgical resection is beneficial with respect to
outcome. For example, pre-operative radiochemotherapy
has been shown to be superior to postoperative radio-
therapy in stage II-III tumors reducing local failure rates
from 13% to 6% in the preoperative arm [2,3]. It should
be followed by surgical resection and adjuvant che-
motherapy. In this concept, toxicity is substantially
lower than with postoperative radiochemotherapy, and
significant downstaging can be achieved with radioche-
motherapy prior to surgery. In the preoperative concept
as well as in the postoperative radiation treatment, gen-
erally, doses of 45 Gy with a boost of 5.4 - 9 Gy to the
macroscopic tumor or tumor bed are applied. Short
course radiotherapy with 5x5 Gy is another alternative
which can be performed prior to surgical resection, and
has shown significant reduction of local recurrences
compared to surgery alone [4-10].
Advances in surgical techniques such as the establish-
ment of the total mesorectal excision (TME) in combi-
nation with advanced radiation and chemotherapy have
reduced local failure rates to few percent only [8,11,12].
However, recurrences do occur, and treatment options
at this stage can be limited due to the size and location
of the lesion, as well as due to previously performed
treatments including radiation therapy.
Surgical resection should be evaluated in all instances,
and can be a treatment option in this situation for cer-
tain patients [13]. However, in some cases a resection is
not possible, or medical reseasons such as concomitant
illnesses restrain the surgeon from surgical interven-
tions. In other cases, surgery is performed, but a gross
resection is not possible and macroscopic tumor
remains which requires adjuvant treatment.
With advanced photon techniques delivering doses
precisely through three-dimensional CT- and MR-based
treatment planning, re-irradiation can be performed for
recurrent rectal cancer, however, doses are commonly
limited to 36 - 45 Gy applied with small safety margins
due to the normal tissue exposure during prior radio-
therapy. In the past, neutrons had been used for the
treatment of recurrent rectal cancer; clinical results with
respect to pain control and and local progression-free
survival were between 50 and 85% in the different cen-
ters [14,15].
Particle therapy using protons or carbon ions offers
distinct physical and biological properties compared to
photon radiotherapy. The physical characteristics
include a low dose deposition within the entry channel
of the particle beam, followed by a steep dose deposition
called the Bragg Peak, which is followed by a sharp dose
fall-off. Additionally carbon ions offer significant biologi-
cal advantages through severe radiation damage per-
formed within the irradiated cells which are difficult to
repair by the cells’ intrinsic repair mechanisms. For var-
ious cell lines, RBE values between 2 and 5 have been
reported depending on the cell line and endpoint.
Therefore, carbon ion radiotherapy is characterised by a
higher relative biological effectiveness (RBE) which can
translate into improved clinical results.
Carbon ion radiotherapy was available by the Depart-
ment of Radiation Oncology at the Gesellschaft für
Schwerionenforschung (GSI) in Darmstadt since 1997.
Superior treatment results for a number of tumor enti-
ties, such as chordomas and chondrosarcomas of the
skull base, as well as adenoid cystic carcinomas (ACC)
have been shown, and carbon ion radiotherapy is cur-
rently performed in the clinical routine for these
patients [16-19]. Safety of carbon ion radiotherapy with
respect to critical organs at risk, such as the brain,
brainstem or spinal chord, have been shown in these
studies. At the Heidelberg Ion Therapy Center (HIT),
treatment of over 1300 patients per year with proton
and carbon ion RT is possible.
In Japan, carbon ion treatment has been available for
over 15 years, and over 5000 patients with different indi-
cations have been treated successfully showing excellent
clinical results [20,21]. For recurrent rectal cancer,
excellent local control rates significantly higher than
those obtained after surgical resection have been
achieved with carbon ions; mostly, these patients were
all initially diagnosed with stage I tumors not treated
with radiation and/or chemotherapy after primary
diagnosis.
Due to the beneficial dose distributions generated by
the particle beam and the higher RBE with carbon ions,
the use of carbon ion radiotherapy for recurrent rectal
carcinoma is a promising treatment alternative in this
patient population. To date, few reports have focussed
on re-irradiation using percutaneous photons or intrao-
perative radiotherapy with electrons in patients with
recurrent rectal cancer.
In general, recurrent rectal cancers are treatment-
resistant tumors, and local high-dose radiation treat-
ment is often limited by organs at risk as well as
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Japanese studies using carbon ion radiotherapy for the
treatment of recurrences from rectal cancer previously
not treated with radiation have shown excellent local
control rates which are superior to conventional radia-
tion therapy as well as surgery alone.
In a first step, a dose-escalation study had been per-
formed from 67.2 Gy E to 73.6 Gy E in 16 fractions.
Local control rates were 93.7% at 5 years at the dose
level of 73.6 Gy E with very low rates of treatment
related acute or chronic side effects [20,21]. However,
these patients had not been treated with prior radiother-
apy, due to the tumor stage they had only been treated
with surgical resection after primary diagnosis.
Therefore, the concept of carbon ion radiotherapy to
patients with recurrent rectal cancer with a macroscopic
tumor lesion after aggressive primary treatment includ-
ing radiotherapy is a promising treatment alternative.
Due to the physical properties of the particle beam,
sparing of normal surrounding tissue supports the use
of this concept as re-irradiation in patients with recur-
rent rectal cancer.
Therefore, in the PANDORA-01-Study, this concept
will be evaluated; in the first step, the recommended
dose will be determined in a dose escalation scheme
(Phase I part) prior to the Phase II part of the study.
Due to the dose escalation part within this prospective
study, the safety of a recommended dose (RD) of carbon
ion radiotherapy will be determined using a classical 3 +
3 design. Within the Phase II part, the RD outcome
after carbon ion radiotherapy will be evaluated. Results
will then be compared to historical controls treated with
surgery alone or with conventional radiation techniques
or Intraoperative Electron Radiotherapy (IOERT).
Patients will be monitored regularly to observe and eval-
uate treatment outcome and side effects.
At the University of Heidelberg, patients with rectal
cancer are treated in the interdisciplinary setting con-
sisting of visceral surgeons, medical oncologist and
radiation oncologist. Therefore, patients will be provided
the best possible oncological care on a professional
basis.
Methods and design
The purpose of the trial is to determine the MTD for
carbon ion radiotherapy for the treatment of recurrent
rectal cancer and to determine feasibility of this treat-
ment in patients with recurrent rectal cancer.
Primary objective
Phase I
The primary endpoint is any Grade IV toxicity related
to the study treatment according to CTCAE Grade 4.0.
Phase II
The primary endpoint is progression-free survival after
re-irradiation at 12 months.
Secondary objectives
Phase I
The secondary endpoint in the Phase I part is progres-
sion-free survival after re-irradiation
Phase II
The secondary endpoints in the Phase II part are overall
survival, toxicity and safety.
Trial design
The trial will be performed as a single-center one-armed
Phase I/II study.
Phase I: Dose escalation
Patients fulfilling the inclusion criteria will be treated
with increasing total doses of carbon ion radiotherapy to
evaluate the optimal carbon ion dose with respect to
toxicity. The aim of this part is to determine the MTD
of carbon ion radiotherapy for re-irradiation of recurrent
rectal cancer.
Patients will be treated within seven increasing dose
regimens starting at 12 × 3 GyE up to 18 × 3 GyE.
Phase II: Treatment with RD
Patients fulfilling the inclusion criteria will be included
into the Phase II part of the study and treated with the
MTD determinated in the Phase I part.
Trial duration and schedule
Phase I dose escalation part
The primary endpoint is toxicity measured by any Grade
IV toxicity related to the study treatment according to
CTCAE Grade 4.0. A maximum of 45 patients are pro-
jected for the Phase I part of the study. Patients will be
followed for at least 3 months after study treatment to
document any toxicity according to CTCAE Version 4.0.
Phase II part
The primary endpoint is progression-free survival after
re-irradiation at 12 months, therefore patients are fol-
lowed within the trial protocol for a minimum 12
months after completion of study treatment. For the
LPI, the final study visit will be 12 months after study
treatment to assess the primary endpoint. All other
patients will be followed on a regular basis as stated
below until death or until 12 months after LPI.
After RT, patients are scheduled for follow-up visits
every 2 months or as needed clinically including con-
trast-enhanced MRI or CT, thorough clinical assessment
as well as evaluation of blood values including CEA.
The last patient included into the study will be fol-
lowed 12 months after treatment. This is considered the
final study visit. All other patients will be followed
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months after LPI.
The overall duration of the trial is expected to be
approximately 36 months. Recruitment of the patients is
planned over a time period of 24 months, minimum
duration of the follow-up phase will be 12 months.
Patient selection: Inclusion and exclusion criteria
General criteria for patients’ selection
Patients with the diagnosis of recurrent rectal cancer
will be evaluated and screened for the protocol. All
patients fulfilling the inclusion and exclusion criteria
will be informed about the study. Patients will be
included according to the incidental gender distribution
for patients with recurrent rectal cancer, male and
female patients will be included.
Inclusion criteria
Patients meeting all of the following criteria will be con-
sidered for admission to the trial:
- Locally recurrent rectal cancer
- Inoperable lesion
- Macroscopic tumor up to 1000 ml volume
- Prior photon irradiation of 20-60 Gy
- Time between initial radiotherapy and re-irradiation
of at least 12 months
- Age ≥ 18 years of age
- Karnofsky Performance Score ≥60
- For women with childbearing potential, (and men)
adequate contraception.
- Ability of subject to understand character and indivi-
dual consequences of the clinical trial
- Written informed consent (must be available before
enrolment in the trial)
Exclusion criteria
Patients presenting with any of the following criteria will
not be included in the trial:
- Refusal of the patients to take part in the study
- Advanced metastatic disease
- Patients who have not yet recovered from acute toxi-
cities of prior therapies.
- Known carcinoma < 5 years ago (excluding Carci-
noma in situ of the cervix, basal cell carcinoma, squa-
mous cell carcinoma of the skin) requiring immediate
treatment interfering with study therapy.
- Pregnant or lactating women
- Participation in another clinical study or observation
period of competing trials, respectively.
Prior and concomitant treatments
During radiation therapy, the application of steroids or
other supportive medication might be necessary due to
the nature of the disease. Addtionally, medication
required for the individual patient for the underlying
illness or for concomitant illnesses (i.e. hypertension,
thyroid disease, hyperlipidemia etc.) can be applied.
Concomitant medication should be discussed with the
principal investigator on an individual basis.
No concomitant chemotherapy or any other anti-
tumor medication is allowed during the treatment per-
iod in this trial.
Radiation therapy
Treatment planning
For particle therapy, patients will be immobilized using
an individual fixation system. For treatment planning,
contrast-enhanced CT as well as MR-imaging will be
performed for optimal target definition.
Patients included to the study will have received 20-60
Gy of photon RT.
Organs at risk such as the small intestine, bladder,
spinal chord and cauda will be contoured. Dose con-
straints of normal tissue will be respected according to
Emami et al. [22]. The Gross Tumor Volume (GTV)
will be defined for the carbon ion treatment as the area
of contrast enhancement on T1-weighted MR-imaging;
the Clinical Target Volume (CTV) will be defined as the
GTV adding a safety margin of 5-10 mm depending on
the clinical situation and the location of the lesion to
account for potential microscopic spread.
A planning target volume (PTV) will be added depend-
ing on individual factors such as patient positioning or
beam angles chosen and will be between 3 and 10 mm.
FDG-PET or SPECT-Examinations may be used in
addition to contrast-enhanced MRI for target volume
definition but are not mandatory.
Carbon ion RT planning is performed using the treat-
ment planning software PT-Planning (Siemens, Erlan-
gen, Germany) including biologic plan optimization.
Biologically effective dose distributions will be calculated
using the a/ß ratio for rectal cancer as well as for the
endpoint late toxicity.
No interruptions > 4 days are allowed.
Patient positioning prior to particle therapy will be
evaluated by comparison of x-rays to the DRRs. Set up
deviations > 3 mm are corrected prior to radiotherapy.
Dose prescription experimental (carbon) arm
The intensity-controlled rasterscan system will be used
for beam application. Single fractions of 3 Gy E will be
applied up to the total dose in the dose escalation
cascade.
Seven dose levels are planned within the Phase I part:
12 × 3 Gy E
13 × 3 Gy E
14 × 3 Gy E
15 × 3 Gy E
16 × 3 Gy E
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18 × 3 Gy E
T h ed o s ew i l lb ep r e s c r i b e dt ot h em a x i m u mo ft h e
calculated dose distribution for the target volume
(PTV). Treatment planning aims in the coverage of the
PTV by the 90%-isodose line.
Dose specification is based on biologic equivalent dose
because of the high relative biologic effectiveness (RBE)
of carbon ions, which differs throughout the target
volume due to its dependence on various factors. RBE
will be calculated at each voxel throughout the target
volumes and biological optimization will be performed.
The dose prescription used is related to the isoeffective
dose GyE (Gray equivalent) using daily fractions of 2 Gy
and a weekly fractionation of 5 × 2 Gy.
After the RD has been determined, this dose will be
the prescribed dose in the Phase II part of the study.
Treatment assignment
Radiation therapy according to the protocol will be per-
formed in patients included into the study.
Patients withdrawn from the trial retain their identifi-
cation codes. New patients must always be allotted a
new identification code.
Assessment of efficacy parameters
Progression-free survival
Efficacy of the treatment will be recorded according to
the RECIST Criteria.
Baseline documentation of “target” lesion
￿ The main target lesion is defined as the macroscopic
tumor delineated for treatment with carbon ion
radiotherapy.
￿ A sum of the longest diameter (LD) for the target
lesions will be calculated and reported as the baseline
sum LD. The baseline sum LD will be used as reference
by which to characterize the objective tumor.
￿ All other lesions (or sites of disease) should be iden-
tified as non-target lesions and should also be recorded
at baseline. Measurements of these lesions are not
required, but the presence or absence of each should be
noted throughout follow-up.
Evaluation of the target lesion
￿ Complete Response (CR): Disappearance of the target
lesions
￿ Partial Response (PR): At least a 30% decrease in the
s u mo ft h eL Do ft h et a r g e tl e s i o n ,t a k i n ga sr e f e r e n c e
the baseline sum LD
￿ Stable Disease (SD): Neither sufficient shrinkage to
qualify for PR nor sufficient increase to qualify for PD,
taking as reference the smallest sum LD since the treat-
ment started
￿ Progressive Disease (PD): At least a 20% increase in
the sum of the LD of the target lesion, taking as refer-
ence the smallest sum LD recorded since the treat-
ment started or the appearance of one or more new
lesions
Evaluation of non-target lesions
￿ Complete Response (CR): Disappearance of all non-tar-
get lesions and normalization of tumor marker level
￿ Incomplete Response/Stable Disease (SD): Persistence
of one or more non-target lesion(s) or/and maintenance
of tumor marker level above the normal limits
￿ Progressive Disease (PD): Appearance of one or more
new lesions and/or unequivocal progression of existing
non-target lesions
Evaluation of best overall response
The best overall response is the best response recorded
from the start of the treatment until disease progres-
sion/recurrence (taking as reference for PD the smallest
measurements recorded since the treatment started). In
general, the patient’s best response assignment will
depend on the achievement of both measurement and
confirmation criteria
￿ Patients with a global deterioration of health status
requiring discontinuation of treatment without objective
evidence of disease progression at that time should be
classified as having “symptomatic deterioration”.E v e r y
effort should be made to document the objective pro-
gression even after discontinuation of treatment.
￿ In some circumstances it may be difficult to distin-
guish residual disease from normal tissue. When the
evaluation of complete response depends on this deter-
mination, it is recommended that the residual lesion be
investigated (fine needle aspirate/biopsy) to confirm the
complete response status.
Survival
Survival is a secondary endpoint of the study. The dura-
tion of survival is the time interval between beginning
of carbon ion radiotherapy and the dated of death due
to any cause. Patients not reported dead or lost to fol-
low-up will be censored at the date of the last follow-up
examination.
Assessment of safety parameters
This study will use the International Common Termi-
nology Criteria for Adverse Events (CTCAE) version 4.0
for toxicity and adverse event reporting. A copy or the
CTCAE can be accessed from the CTEP home page.
Safety and toxicity of the study treatment will be eval-
uated by clinical examination as well as imaging studies
(MRI or CT).
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The following parameters will be collected and taken
into account in: CEA, age, Karnofsky Performance
Score, lesion size.
Plan for treatment or care after the trial
After completion of study treatment, no further treat-
ment is planned and patients wtill be followed up regu-
larly. Follow-up examinations include clinical
assessment, contrast-enhanced imaging with MRI or
CT, and evaluation of blood values including CEA.
Patients will be seen every 2 months after treatment or
as needed clinically.
Any systemic treatment or chemotherapy is not part
of the clinical trial.
For tumor progression, treatment alternatives will be
evaluated and discussed interdisciplinary considering
options of surgical resection, systemic treatment such as
chemotherapy, a third course of radiation therapy, or
other.
Statistical considerations
This section describes the considerations underlying the
choice of the sample size as well as the statistical meth-
odology applied for the analysis of the Phase I and the
Phase II part of the PANDORA-01 study. By combining
the Phase I and Phase II part within a single study, the
results of those 9 patients that received the MTD within
the Phase I part can be used for the assessment of the
efficacy in the Phase II part. Therefore, the required
sample size of the Phase II part can be reduced, which
is highly desirable from an ethical point of view. More
details on the evaluation can be found in the statistical
analysis plans prepared for the two study parts which
will be finalized prior to performing any analyses and
which have to be authorized by the study biostatistician
and the principal investigator.
Phase I part of PANDORA-01
It is the aim of the Phase I part of this study to deter-
mine the MTD for carbon ion radiotherapy for the
treatment of recurrent rectal cancer. The primary end-
point is the occurrence of a dose limiting toxicity
defined as any Grade IV toxicity according to CTCAE
Version 4.0, possibly, probably or definitely associated to
study treatment and occurring during 30 days after
completion of the study treatment.
The calculation of the sample size for the Phase I part
of the PANDORA-01 trial is based on the traditional 3
+ 3 dose escalation scheme which is conducted as
follows:
Patients are treated in cohorts of three each receiving
the same dose. For the assessment of a dose limiting
toxicity (see definition above) patients are observed for
30 days after application of the study treatment.
If none of the three patients of a cohort exhibits a
dose limiting toxicity, the next cohort of three patients
receives the next higher dose.
Otherwise, if at least one patient of a cohort exhibits a
dose limiting toxicity, a further cohort of three patients
is treated at the same dose level without escalating the
dose.
If exactly one out of the six patients treated at this
dose exhibits a dose limiting toxicity, the trial continues
as planned at the next higher dose level.
If two or more patients out of the six patients treated
at this dose exhibit a dose limiting toxicity, the dose
escalation stops at that level and the next lower dose is
considered as the MTD. When the escalation has
stopped, additional patients will be treated at the MTD
to a total of nine patients.
The Phase I part of the trial is conducted to determine
the MTD of carbon ion radiotherapy by consideration of
a total of seven dose levels. Therefore, the maximum
sample size is 45 patients (six dose levels with a maxi-
mum of 6 patients each and 9 patients at the MTD).
Primary endpoint to determine the MTD that is cho-
sen out of seven dose levels is any Grade IV toxicity
according to CTCAE Version 4.0, possibly, probably or
definitely associated to study treatment and occurring
during 30 days after completion of the study treatment.
Secondary endpoints are other safety data on the applied
dose levels as well as response, progression-free survival,
and overall survival.
Phase II part of PANDORA-01
The primary objective of the Phase II part of PAN-
DORA-01 is to evaluate the 12 month progression-free
survival rate π for patients with recurrent rectal cancer
receiving carbon ion radiotherapy. According to results
reported in the literature, the 12 month progression-free
survival rate for patients treated with conventional
radiotherapy is estimated to be 0.60. Thus, the confir-
matory analysis of the primary endpoint assesses the fol-
lowing test problem: H0: π ≤ 0.60 = π0 versus H1: π >
0.60.
The sample size calculation for the confirmatory ana-
lysis of the Phase II part of the study refers to the test
problem given above that will be assessed applying a
one-sided binomial test at an overall type I error rate of
a =0 . 0 5 .Ap o w e ro f1 - b = 0.80 is aspired for the alter-
native of a 12 month progression-free survival rate of π1
= 0.80, i.e., for an absolute improvement of 0.20 as com-
pared to conventional radiotherapy. As this Phase II part
of PANDORA-01 is the first study providing data on the
efficiency of carbon ion therapy for the treatment of
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with respect to the actual 12 month progression-free
survival rate resulting from carbon ion therapy in this
patient population: The rate may be higher than 0.80
thus requiring fewer patients for the study; or it may be
slightly lower than 0.80 while the improvement may still
be clinically relevant, but with the consequence for the
study that more patients than initially planned would be
required to assure the desired power. For this reason, an
adaptive version of Simon’s optimal two-stage design is
used for this Phase II study part [23,24]. This design
enables to change the initially specified sample size
based on the results of a planned interim analysis. If the
sample size is not modified, a maximum total of 39
patients is included, with an interim analysis after n1 =
14 patients and further n1 = 25 patients recruited for
the second stage if the study is continued after stage 1.
Using the decision rules given, this design assures the
desired power 1- b =0 . 8 0f o rt h ea l t e r n a t i v eπ1 =0 . 8 0
and has an expected sample size of 20.8 under the null
hypothesis π0 = 0.60. According to the design of the
Phase I part of PANDORA-01, 9 patients are already
treated there with the MTD.
The primary outcome variable is the 12 month pro-
gression-free survival rate. Secondary objectives are the
assessment of the 12 month overall survival rate as well
as safety and tolerability.
More details on the statistical analysis will be provided
in the statistical analysis plan which is finalized prior to
performing any analysis and which has to be authorized
by the study biostatistician and the principal
investigator.
Data safety monitoring board (DSMB)
An independent Data and Safety Monitoring Board
(DSMB) will monitor the recruitment, the reported
adverse events and the data quality at least twice a year.
Based on its review the DSMB will provide the Principal
Investigator (PI) with recommendations regarding trial
modification, continuation or termination.
Data collection and management
According to the §13 of the German GCP-Regulation all
important trial documents will be archived for at least
10 years after the end of the PANDORA-01 trial.
According to the §28c of the German X-Ray Regulation
(RöV) and the §87 of the German Radiation Protection
Regulation (StrlSchV) the informed consent forms
including patients’ consent for trial participation, appli-
cation of irradiation and data transmission to the com-
petent authority will be archived for at least 30 years
after the end of the trial. The Study Center at the
Deparment of Radiation Oncology Define will be
responsible for archiving allrelevant data.
Ethical and legal aspects
The protocol will be condected according the guidelindes
of Good Clinical Practice (GCP) and the ethical princi-
ples described in the Declaration of Helsinki (2008 Ver-
sion of the Declaration of Helsinki, adopted at the 59th
WMA General Assembly, Seoul, October 2008).
The trial will be carried out by adhereing to local legal
and regulatory requirements.
The study plan has obtained approval by the Institu-
tional Review Board (IRB)/Independent Ethics Commit-
tee (EC) of the Medical Faculty Heidelberg. Before start
of recruitment a positive vote of the Bundesamt für
Strahlenschutz (BfS) is necessary.
Discussion
The aim of the present PANDORA-01 trial is to evaluate
the MTD for carbon ion radiotherapy in patients with
recurrent rectal cancer, previously treated with radiation;
subsequently, the efficacy of carbon ion radiotherapy will
be evaluated in the Phase II part of the study.
To date, the possibility to treat patients with inoperable
recurrent rectal cancer with radiation as a second course
of radiotherapy had proven only modest effectivity, with a
potential risk of treatment-related side effects
[14,15,25,26]. However, the physical and biological charac-
teristics of the carbon ion beam potentially offer a treat-
ment alternative in this clinical situation. Previous studies
from Japan on carbon ion radiotherapy for rectal cancer
have shown promising results [21,27-29]. However, the
published data focus on carbon ion radiotherapy applied
in radiation-naïve patients. In Europe, the majority of
patients presenting with recurrent rectal cancer have been
treated with radiation during first-line treatment, either
with preoperative chemo-radiation, short-term regimens,
such as 5 × 5Gy, or with adjuvant chemoradiation,
depending on tumor stage and institutional preferences.
Taking all these aspects into consideration, the present
trial was designed as a Phase I/II trial firstly evaluating
the MTD for carbon ion radiotherapy, followed by eva-
luation of efficacy in the Phase II part of the trial.
Carbon ion radiotherapy will be applied using the ras-
terscanning technique. A typical treatment plan can be
Figure 1 Typical treatment plan for carbon ion radiotherapy
applied with the rasterscanning technique in a patients with
locally recurrent rectal cancer axial sagittal and coronal view.
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document all treatment-related side effects, as well as to
assess treatment response and tumor control.
In conclusion, the PANDORA-01 study is the first
trial to evaluation high-LET particle therapy with carbon
ions as re-irradiation in patients with locally recurrent
and unresectable rectal cancer.
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Massachusetts General Hospital; MR: Minor responses; MRI: Magnet
resonance imaging; MTD: Maximal Tolerable Dose; n.a.: Not applicable; NIRS:
National Institute of Radiological Sciences; OS: Overall survival; PR: Partial
response; PTV: Planning target volume; RBE: Relative biological effectiveness;
SD: Stable disease; RT: Radiation therapy; SAE: Severe Adverse Events; TME:
Total Mesorectal Excision.
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